Guo et al. demonstrated that in streptozotocin-induced models of diabetic nephropathy, mice treated with dapagliflozin displayed remission of pathological lesions such as glomerular sclerosis, thickening of the glomerular basement membrane (GBM), podocyte injury in the glomeruli, decreased nephrotoxic levels, and decreased SGLT2 expression. This evidence concerns the gene SLC5A2 and diabetic kidney disease.